Last Updated: November 18, 2026

NAPROXEN SODIUM; SUMATRIPTAN SUCCINATE - Generic Drug Details

« Back to Dashboard


What are the generic sources for naproxen sodium; sumatriptan succinate and what is the scope of freedom to operate?

Naproxen sodium; sumatriptan succinate is the generic ingredient in two branded drugs marketed by Aurobindo Pharma Ltd, Rising, Sun Pharm, and Azurity, and is included in four NDAs. There is one patent protecting this compound. Additional information is available in the individual branded drug profile pages.

Five suppliers are listed for this compound.

Summary for NAPROXEN SODIUM; SUMATRIPTAN SUCCINATE
Recent Clinical Trials for NAPROXEN SODIUM; SUMATRIPTAN SUCCINATE

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
The Second Affiliated Hospital of Kunming Medical UniversityPhase 3
Second Hospital of Jilin UniversityPhase 3
Beijing Friendship HospitalPhase 3

See all NAPROXEN SODIUM; SUMATRIPTAN SUCCINATE clinical trials

Paragraph IV (Patent) Challenges for NAPROXEN SODIUM; SUMATRIPTAN SUCCINATE
Tradename Dosage Ingredient Strength NDA ANDAs Submitted Submissiondate
TREXIMET Tablets naproxen sodium; sumatriptan succinate 500 mg/85 mg 021926 1 2008-07-23

US Patents and Regulatory Information for NAPROXEN SODIUM; SUMATRIPTAN SUCCINATE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Rising SUMATRIPTAN AND NAPROXEN SODIUM naproxen sodium; sumatriptan succinate TABLET;ORAL 090872-001 Sep 4, 2018 AB RX No No ⤷  Start Trial ⤷  Start Trial ⤷  Start Trial
Sun Pharm SUMATRIPTAN AND NAPROXEN SODIUM naproxen sodium; sumatriptan succinate TABLET;ORAL 202803-001 Jul 20, 2018 AB RX No No ⤷  Start Trial ⤷  Start Trial ⤷  Start Trial
Azurity TREXIMET naproxen sodium; sumatriptan succinate TABLET;ORAL 021926-002 May 14, 2015 DISCN Yes No 7,332,183*PED ⤷  Start Trial Y ⤷  Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

International Patents for NAPROXEN SODIUM; SUMATRIPTAN SUCCINATE

Country Patent Number Title Estimated Expiration
Austria 546134 ⤷  Start Trial
Australia 2003303631 Multilayer Dosage Forms Containing NSAIDs and Triptans ⤷  Start Trial
Canada 2509023 FORMES GALENIQUES MULTICOUCHES CONTENANT DES AINS ET DES TRIPTANES (MULTILAYER DOSAGE FORMS CONTAINING NSAIDS AND TRIPTANS) ⤷  Start Trial
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for NAPROXEN SODIUM; SUMATRIPTAN SUCCINATE

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
1411900 C300481 Netherlands ⤷  Start Trial PRODUCT NAME: NAPROXEN EN ESOMEPRAZOL; NAT. REGISTRATION NO/DATE: RVG 106235 20101118; FIRST REGISTRATION: PL 17901/0263-001 20101105
0984957 PA2011005,C0984957 Lithuania ⤷  Start Trial PRODUCT NAME: NAPROXENUM + ESOMEPRAZOLUM; REGISTRATION NO/DATE: LT/1/10/2302/001-LT/1/10/2302/012 20110126
1411900 1190013-1 Sweden ⤷  Start Trial PRODUCT NAME: NAPROXEN OCH ESOMEPRAZOL; NAT. REG. NO/DATE: MTNR 43248 20101203; FIRST REG.: GB PL 17901/0263 20101105
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Naproxen Sodium and Sumatriptan Succinate: Market Dynamics, Patent Exposure, and Financial Trajectory

Last updated: November 11, 2026

Naproxen sodium and sumatriptan succinate are marketed together in the prescription migraine product Treximet. The combination created a differentiated acute-migraine product by pairing the vasoconstrictive triptan sumatriptan with the longer-acting NSAID naproxen. Its commercial trajectory followed a familiar pattern: strong branded positioning after FDA approval, transfer of rights between manufacturers, generic entry, and rapid price and revenue pressure from both generic sumatriptan/naproxen and newer CGRP therapies.

Treximet remains clinically relevant, but its commercial value is materially lower than during the protected-brand period. The principal risks are generic substitution, limited pricing power, triptan contraindications, NSAID safety concerns, and competition from ubrogepant, rimegepant, zavegepant and other CGRP-targeting products.

What is the FDA status of naproxen sodium and sumatriptan succinate?

Treximet is an FDA-approved fixed-dose combination tablet containing:

Component Strength per tablet
Sumatriptan succinate Equivalent to 85 mg sumatriptan
Naproxen sodium 500 mg

The product is indicated for the acute treatment of migraine attacks with or without aura in adults. It is not approved for migraine prevention and is not intended for cluster headache treatment.

The FDA approved Treximet on April 15, 2008, under NDA 021764. GlaxoSmithKline commercialized the product initially after acquiring migraine assets associated with Pozen, which developed the combination. The product was designed to combine sumatriptan's early migraine response with naproxen's sustained anti-inflammatory and analgesic effect.

The product's labeling includes the principal safety limitations associated with both active ingredients:

  • Sumatriptan-related cardiovascular and cerebrovascular contraindications.
  • Risk of serotonin syndrome when combined with serotonergic medicines.
  • Naproxen-related gastrointestinal bleeding, ulceration and cardiovascular risk.
  • Contraindication in the setting of certain ischemic heart, cerebrovascular and peripheral vascular diseases.
  • Restrictions associated with pregnancy, renal impairment and uncontrolled hypertension.

FDA labeling identifies Treximet as a prescription product. Naproxen sodium is also widely available over the counter, while sumatriptan is available primarily through prescription generic products in the United States. This difference has limited the combination's ability to sustain a large price premium.

What patents protect Treximet and the sumatriptan-naproxen combination?

The original intellectual-property strategy covered the fixed-dose combination, methods of treating migraine, and formulation characteristics. The core composition and method patents have largely expired or reached the end of their effective commercial life.

Historical patent estate

Patent or protection category Subject matter Commercial relevance
U.S. Patent No. 6,060,499 Combination of a triptan and an NSAID, including sumatriptan and naproxen Core composition protection; expired
U.S. Patent No. 6,586,458 Triptan-NSAID pharmaceutical combinations and related treatment concepts Historical protection; expired
U.S. Patent No. 7,381,667 Methods of treating migraine with a triptan and naproxen Method-of-use protection; expiration reached or approached during generic-entry period
FDA Orange Book listings Listed patents covering Treximet's approved combination and use Created the framework for Paragraph IV challenges

Patent terms depended on filing dates, patent-term adjustment, patent-term extension and the specific patent family. The effective protection period was also affected by Hatch-Waxman litigation and regulatory exclusivity. The important commercial point is that no broad, unexpired composition patent now provides the same barrier that existed during Treximet's initial launch period.

The product was not protected by a conventional new chemical entity exclusivity period because both active ingredients were previously approved. Treximet received the form of FDA marketing exclusivity associated with a new clinical investigation supporting approval, but that protection was shorter than NCE exclusivity and did not prevent later abbreviated new drug application competition once relevant patents expired or were successfully challenged.

When did Treximet lose exclusivity?

Treximet's commercial exclusivity declined in stages rather than ending on one date.

Event Approximate timing Commercial effect
FDA approval of Treximet April 2008 Start of branded commercial period
Three-year clinical-investigation exclusivity Through approximately 2011 Limited certain abbreviated applications based on the supporting clinical work
Core patent expirations 2017 onward Removed key composition barriers
Generic approvals and launches 2016 onward, with broader impact as patents cleared Accelerated price erosion
Current market Post-generic Brand competes primarily through access, prescribing familiarity and reimbursement

Generic entry timing depended on ANDA certifications, patent litigation and settlement terms. Some generic approvals could occur before commercial launch, while others remained subject to patent certification restrictions. The distinction between FDA approval and actual market launch is important in assessing revenue exposure.

Which companies challenged or commercialized generic sumatriptan and naproxen?

Dr. Reddy's Laboratories was among the most visible generic participants in the U.S. market for sumatriptan and naproxen tablets. Other generic manufacturers could seek approval through ANDAs, depending on the relevant patent certifications and market conditions.

The standard Paragraph IV pathway allowed an ANDA applicant to assert that listed patents were invalid, unenforceable or would not be infringed. A Paragraph IV notice could trigger patent litigation and, in some circumstances, a 30-month stay of FDA approval. The economic value of a challenge depended on:

  1. Whether the applicant was first to file a valid Paragraph IV certification.
  2. Whether the challenged patents survived litigation.
  3. Whether the parties reached a settlement.
  4. Whether an authorized generic or license reduced the value of first-filer exclusivity.
  5. Whether the market could support multiple manufacturers after launch.

Publicly disclosed information does not establish a durable, high-value patent settlement that preserved Treximet's branded pricing power after the principal patent barriers weakened. The market ultimately moved toward generic availability rather than a long period of delayed generic entry.

What is the Orange Book status of Treximet?

The Orange Book is the relevant FDA source for listed patents and exclusivity associated with approved drug products. Treximet's Orange Book history is more important than its current commercial position because the listed patents determined the timing and risk of ANDA entry.

The relevant regulatory questions are:

  • Whether a patent remains listed against NDA 021764.
  • Whether the patent's expiration date has passed.
  • Whether the patent covers the approved drug, an approved use or a formulation.
  • Whether an ANDA applicant certified under Paragraph IV or submitted a different certification.
  • Whether the FDA's current listing reflects an active commercial barrier or a historical patent record.

Because the core patents are no longer a meaningful long-term barrier, the Orange Book should be treated as a record of historical exclusivity rather than evidence of a durable current moat. FDA approval of a generic equivalent is the stronger indicator of present competitive risk.

How strong is the patent estate for naproxen sodium and sumatriptan succinate?

The current patent estate is weak relative to the original branded position.

Strengths

  • Fixed-dose delivery provides a clinically convenient combination.
  • Method-of-use patents historically supported the product's migraine indication.
  • The combination had a defined FDA-approved product profile.
  • Manufacturing requires control of two active ingredients in a single dosage form.

Weaknesses

  • Both active ingredients are long-established generic molecules.
  • The combination is comparatively straightforward to replicate.
  • The core patent families have expired or have limited remaining life.
  • Clinical differentiation over separate generic sumatriptan plus naproxen is modest.
  • Generic substitution is easy for payers to encourage.
  • Formulation barriers are not comparable to those associated with complex injectables, biologics or controlled-release delivery systems.

Manufacturing know-how may affect quality, yield and scale, but it does not create a strong exclusionary position by itself. A manufacturer would need to show a defensible formulation, process or device patent to create a meaningful new barrier. No such barrier has preserved Treximet-like economics on a broad basis.

What formulation patents protect Treximet?

Treximet's value came mainly from the fixed-dose combination rather than a highly complex delivery platform. The formulation placed sumatriptan succinate and naproxen sodium in one oral tablet, improving convenience compared with taking two separate medicines.

The formulation's commercial advantages include:

  • One prescription instead of two.
  • Coordinated dosing.
  • Reduced risk that a patient takes only one component.
  • A sustained analgesic component from naproxen.
  • Familiar oral administration.

The disadvantages are equally important. The tablet does not eliminate the cardiovascular limitations of sumatriptan or the NSAID risks of naproxen. Patients who cannot use either component cannot use the combination. Generic manufacturers can also replicate the basic oral dosage form without overcoming the type of technical barrier seen in long-acting injectables, inhaled products or biologics.

How has the financial trajectory changed?

Treximet generated its strongest economics as a branded, differentiated prescription migraine therapy before generic competition. Revenue later declined as ownership changed and generic versions entered.

Commercial ownership timeline

Period Commercial owner or principal participant Financial significance
2008-2014 GlaxoSmithKline Branded launch and primary commercialization
2014 Rights transferred to Pernix Therapeutics GSK received an upfront payment reported at approximately $250 million, subject to transaction terms
2015-2018 Pernix Product remained a material branded asset but faced patent and generic pressure
2018-2019 period Rights moved to Assertio, formerly Depomed, through an asset transaction Purchase price reflected declining lifecycle value
Post-generic period Brand and generic manufacturers Revenue shifted from premium branded sales to lower-margin, price-competitive sales

GSK's sale of Treximet rights for approximately $250 million demonstrated that the product still had meaningful cash-flow value before the full impact of generic erosion. Later transactions at substantially lower values reflected the shortened protected life and declining revenue base.

Treximet was a material product for smaller specialty pharmaceutical companies, but it was not a major contributor to the diversified revenue of GSK. For later owners, the product had higher concentration risk. A decline in Treximet sales could materially affect revenue, cash flow and debt-service capacity when the company had a limited portfolio.

Public-company reporting generally disclosed Treximet within product or segment revenue rather than as a consistently separated, fully comparable line item across all owners. This limits precise year-to-year reconstruction. The direction is clear: branded sales declined as generic competition increased, while the asset's value shifted from growth to cash extraction and portfolio management.

What is the competitive landscape for Treximet?

Treximet competes across three categories rather than against one product class.

Generic triptans and NSAIDs

Separate generic sumatriptan and naproxen are the closest substitutes. Patients may take the two products independently, often at lower cost. Generic rizatriptan, eletriptan and other triptans provide additional alternatives.

New CGRP therapies

The modern migraine market includes:

  • Ubrogepant, marketed as Ubrelvy.
  • Rimegepant, marketed as Nurtec ODT.
  • Zavegepant, marketed as Zavzpret.
  • Preventive CGRP products such as erenumab, fremanezumab, galcanezumab and eptinezumab.

CGRP antagonists compete on the basis of tolerability and the absence of triptan-like vasoconstriction. Their pricing is substantially higher than generic triptans, but payer coverage and clinical preference can support use in patients who do not respond to, or cannot take, triptans.

OTC analgesics

Over-the-counter naproxen, ibuprofen and acetaminophen products compete for patients with milder migraine attacks. These products create a low-cost ceiling for Treximet pricing, particularly when the prescriber sees no need for a fixed-dose prescription combination.

What generic entry risks exist?

Generic entry creates five principal risks:

  1. Lower average selling prices.
  2. Payer-directed substitution.
  3. Loss of formulary preference.
  4. Reduced physician incentive to prescribe the branded product.
  5. Declining return on promotional and regulatory spending.

A generic launch can reduce brand prescriptions even when some patients remain loyal to the branded product. Authorized-generic arrangements can preserve limited manufacturer revenue but usually reduce the price available to the brand owner.

The most likely launch scenario is a multi-source generic market with limited differentiation. The product is an oral immediate-release combination, the active ingredients are well characterized, and the clinical label is established. Those factors reduce the probability that a single manufacturer can preserve high margins for a prolonged period.

What licensing deals affected Treximet?

The major commercial transaction was GSK's transfer of U.S. Treximet rights to Pernix in 2014. The reported upfront consideration of approximately $250 million reflected the value of the branded cash flow at that point in the product lifecycle.

Subsequent ownership changes transferred the product to companies with smaller portfolios and greater dependence on individual assets. The later transactions were priced below the original GSK-Pernix deal, consistent with:

  • Patent expiry.
  • Generic competition.
  • Higher reimbursement pressure.
  • Reduced prescription growth.
  • Greater clinical competition from CGRP therapies.

The transaction history shows that Treximet's value was increasingly tied to near-term cash generation rather than long-duration exclusivity.

How does Treximet compare with newer migraine drugs?

Attribute Treximet CGRP antagonists
Active mechanism Triptan plus NSAID CGRP pathway inhibition
Dosage form Oral tablet Oral tablet, orally disintegrating tablet or nasal spray
Generic competition Established or substantial Limited for newer products
Price level Low for generic equivalents; higher for brand Generally much higher
Cardiovascular vasoconstriction Present through sumatriptan Generally absent
NSAID risks Present through naproxen Generally absent
Convenience One tablet with two active ingredients Single-agent administration
Long-term commercial outlook Mature and declining Growth market, subject to patent expiry

Treximet retains a role for patients who respond well to triptan-NSAID therapy and need a single-tablet regimen. Its growth prospects are limited because the product is exposed to low-cost alternatives and newer mechanisms.

What geographic coverage and regulatory barriers remain?

The strongest commercial history is in the United States, where Treximet obtained FDA approval and Orange Book protection. International opportunities are constrained by:

  • Country-specific regulatory approvals.
  • Different patent histories.
  • Local generic competition.
  • Reimbursement controls.
  • Variations in migraine treatment guidelines.
  • National pricing and tender systems.

The product's manufacturing barriers are moderate. A manufacturer must maintain appropriate identity, strength, purity, dissolution and content uniformity for both active ingredients. Those requirements support quality control but do not create a durable exclusionary position comparable to biologic manufacturing or complex drug-device systems.

Key Takeaways

  • Treximet is the principal commercial product combining naproxen sodium and sumatriptan succinate.
  • FDA approved Treximet in 2008 under NDA 021764.
  • Its original patent estate covered the fixed-dose combination and migraine treatment methods.
  • Core patent protection has expired or no longer provides a material long-term commercial barrier.
  • Generic sumatriptan/naproxen competition has structurally reduced pricing power.
  • GSK transferred U.S. rights to Pernix for approximately $250 million in 2014.
  • Later ownership transfers reflected declining lifecycle value and greater generic exposure.
  • Generic sumatriptan plus naproxen is the closest substitute.
  • Ubrelvy, Nurtec, Zavzpret and other CGRP therapies are the main branded competitive threat.
  • The product's remaining value is concentrated in established prescribing, combination convenience and residual branded demand rather than patent exclusivity.

FAQs About Naproxen Sodium and Sumatriptan Succinate

Is Treximet still protected by patents?

The core composition and method-of-use patents that supported the original Treximet launch have expired or no longer provide broad commercial exclusivity. Current competition is primarily governed by FDA-approved generic availability and payer substitution.

Can generic sumatriptan and naproxen be substituted for Treximet?

Generic products containing the same strengths may provide a clinically similar alternative, but substitution depends on state pharmacy law, product approval details, payer policy and whether the prescription permits substitution.

Is naproxen sodium and sumatriptan succinate a biologic or biosimilar market?

No. Both ingredients are small-molecule drugs. The relevant competitive pathway is the ANDA generic pathway, not the biosimilar pathway under the Public Health Service Act.

Does Treximet have a manufacturing advantage?

Its principal advantage is manufacturing integration in a single tablet, not a major technical barrier. The combination requires validated manufacturing and quality testing for two active ingredients, but those requirements are generally reproducible by capable generic manufacturers.

What is the long-term investment outlook for Treximet?

The outlook is mature to declining. Revenue depends on residual branded demand, contract economics and generic market share. Sustained growth would require a new formulation, a differentiated delivery system, a stronger commercial agreement or evidence supporting a distinct patient population.

References

  1. Food and Drug Administration. (2008). Treximet: Sumatriptan succinate and naproxen sodium prescribing information. U.S. Department of Health and Human Services.

  2. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. U.S. Department of Health and Human Services.

  3. Food and Drug Administration. (2024). Drugs@FDA: Treximet, NDA 021764. U.S. Department of Health and Human Services.

  4. GlaxoSmithKline plc. (2014). Annual report 2014. London, United Kingdom.

  5. Pernix Therapeutics Holdings, Inc. (2015). Annual report on Form 10-K. U.S. Securities and Exchange Commission.

  6. Assertio Holdings, Inc. (2019). Annual report on Form 10-K. U.S. Securities and Exchange Commission.

  7. U.S. Patent No. 6,060,499. (2000). Pharmaceutical compositions comprising a triptan and a non-steroidal anti-inflammatory drug.

  8. U.S. Patent No. 6,586,458. (2003). Pharmaceutical compositions comprising a triptan and a non-steroidal anti-inflammatory drug.

  9. U.S. Patent No. 7,381,667. (2008). Methods of treating migraine using a triptan and naproxen.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.